Literature DB >> 8172823

Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement.

M E Williams1, S H Swerdlow.   

Abstract

BACKGROUND: Approximately 70% of centrocytic (mantle-cell) lymphomas have the chromosomal translocation t(11;14) (q13; q32) and associated rearrangements at the bcl-1 breakpoint locus and at the cyclin D1 (PRAD1, CCND1) gene, thus implicating this gene in the pathogenesis of centrocytic lymphoma. In order to determine cyclin D1 expression in hematopoietic neoplasms with and without bcl-1 or cyclin D1 rearrangements, northern blot analysis was performed.
METHODS: Total RNA was isolated from peripheral blood cells of patients with hematopoietic neoplasms in leukemic phase, including three patients with B-cell lymphoma containing chromosome 11q13 bcl-1 rearrangements. Northern blots were hybridized with a cyclin D1 cDNA probe and the degree of mRNA expression determined.
RESULTS: Each of the bcl-1-rearranged cases showed high levels of cyclin D1 expression, whereas no expression was detected in RNA from samples of B-cell CLL, T-cell prolymphocytic leukemia, or acute nonlymphocytic leukemia which lacked bcl-1 or cyclin D1 rearrangement.
CONCLUSIONS: Overexpression of cyclin D1, a G1 cyclin implicated in cell-cycle regulation, may play a critical role in the pathogenesis of t(11; 14)-positive lymphomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172823     DOI: 10.1093/annonc/5.suppl_1.s71

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

Review 1.  New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders.

Authors:  E Matutes
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

Review 2.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

3.  Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Authors:  Hilka Rauert-Wunderlich; Anja Mottok; David W Scott; Lisa M Rimsza; German Ott; Wolfram Klapper; Michael Unterhalt; Hanneke C Kluin-Nelemans; Olivier Hermine; Sylvia Hartmann; Christoph Thorns; Grzegorz Rymkiewicz; Harald Holte; Martin Dreyling; Eva Hoster; Andreas Rosenwald
Journal:  Br J Haematol       Date:  2018-08-10       Impact factor: 6.998

4.  Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.

Authors:  A McShea; P L Harris; K R Webster; A F Wahl; M A Smith
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

5.  Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma.

Authors:  Yuan Ke; Cheng-Gong Liao; Zheng-Qing Zhao; Xiao-Min Li; Rong-Jie Lin; Long Yang; He-Long Zhang; Ling-Min Kong
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

6.  Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement.

Authors:  Cheng-Han Lee; Rola H Ali; Marjan Rouzbahman; Adrian Marino-Enriquez; Meijun Zhu; Xiangqian Guo; Alayne L Brunner; Sarah Chiang; Samuel Leung; Nataliya Nelnyk; David G Huntsman; C Blake Gilks; Torsten O Nielsen; Paola Dal Cin; Matt van de Rijn; Esther Oliva; Jonathan A Fletcher; Marisa R Nucci
Journal:  Am J Surg Pathol       Date:  2012-10       Impact factor: 6.394

7.  Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.

Authors:  Mitchell R Smith; Hailun Li; Leo Gordon; Randy D Gascoyne; Elisabeth Paietta; Andres Forero-Torres; Brad S Kahl; Ranjana Advani; Fangxin Hong; Sandra J Horning
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

Review 8.  Targeting CDK4 and CDK6: From Discovery to Therapy.

Authors:  Charles J Sherr; David Beach; Geoffrey I Shapiro
Journal:  Cancer Discov       Date:  2015-12-11       Impact factor: 39.397

9.  CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.

Authors:  Hilka Rauert-Wunderlich; Martina Rudelius; Ingolf Berberich; Andreas Rosenwald
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

10.  Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment.

Authors:  Viktoria Fuhr; Ehsan Vafadarnejad; Oliver Dietrich; Panagiota Arampatzi; Angela Riedel; Antoine-Emmanuel Saliba; Andreas Rosenwald; Hilka Rauert-Wunderlich
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.